| mechanism | treatment | Demonstrated benefit and harm | k | | | |
|---|
| angiotensin-Converting Enzyme Inhibitors | captopril | versus placebo or control No demonstrated result for efficacy | 5 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| SAVE, 1992 | captopril vs placebo | | | | | captopril vs placebo | | | | | captopril vs placebo | | | | | captopril vs placebo | | | | | captopril vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| SAVE, 1992 | Captopril 12·5 mg initial dose, up to 25–50 mg three times daily (n=1115) vs. placebo (n=1116) | patient within 3–16 days of a MI, LVEF <40% | double blind Parallel groups Sample size: 1115/1116 Primary endpoint: Mortality from all causes FU duration: 3.5y | | Pfeffer, 1988 | Captopril (n=38) vs. placebo (n=0) | patient within 11-31 days after MI, LVEF<=45%, not in overt congestive heart failure | double blind Parallel groups Sample size: 38/0 Primary endpoint: hemodynamic function and left ventricular volume FU duration: 1 year | | Sogaard, 1994 | Captopril 50mg daily (n=58) vs. placebo (n=0) | patients with left ventricular (LV) dysfunction on day 7 after MI | double blind Parallel groups Sample size: 58/0 Primary endpoint: Ventricular arrhythmias FU duration: 6 months | | Sharpe, 1988 | Captopril 25 mg thrice a day (n=60) vs. placebo (n=0) | patients with symptomless left ventricular dysfunction (LVEF<45%) 1 week after a myocardial infarction without clinical evidence of heart failure | double blind Parallel groups Sample size: 60/0 Primary endpoint: left ventricular volumes FU duration: 1 year | | Mortarino, 1990 | Captopril 25 mg bid (n=10) vs. placebo (n=11) | patient with mild congestive heart failure after recent MI | double blind Parallel groups Sample size: 10/11 Primary endpoint: none FU duration: 2 months |
|
| angiotensin-Converting Enzyme Inhibitors | ramipril | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| AIRE, 1993 | ramipril vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| AIRE, 1993 | Ramipril 2·5 mg twice daily initial dose, up to 5 mg twice daily for at least 6 months (n=1004) vs. placebo (n=992) | patient within 3–10 days of a MI,with clinical evidence of heart failure | Double blind Parallel groups Sample size: 1004/992 Primary endpoint: FU duration: 1.25 y |
|
| angiotensin-Converting Enzyme Inhibitors | trandolapril | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| TRACE, 1995 | trandolapril vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| TRACE, 1995 | Trandolapril 1 mg daily initial dose, up to 4 mg daily (n=876) vs. placebo (n=873) | patient within 3–7 days of a MI,Wall motion index <1·2 (LVEF <35%) | Double blind Parallel groups Sample size: 876/873 Primary endpoint: death from any cause FU duration: 3 y |
|
